Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

被引：15
|
作者：
Bardia, Aditya
Krop, Ian
Meric-Bernstam, Funda
Tolcher, Anthony W.
Mukohara, Toru
Lisberg, Aaron
Shimizu, Toshio
Hamilton, Erika
Spira, Alexander I.
Papadopoulos, Kyriakos P.
Greenberg, Jonathan
Gu, Wen
Kobayashi, Fumiaki
Zebger-Gong, Hong
Kawasaki, Yui
Wong, Rie
Kogawa, Takahiro
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-10-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-03
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study
    Schmid, Peter
    Wysocki, Piotr
    Ma, Cynthia
    Park, Yeon H.
    Fernandes, Ricardo
    Lord, Simon
    Baird, Richard D.
    Prady, Catherine
    Jung, Kyung Hae
    Asselah, Jamil
    Huisden, Robert
    Stewart, Ross
    Vukovic, Petra
    Nunes, Ana T.
    Nowecki, Zbigniew
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
    Schmid, P.
    Jung, K. H.
    Wysocki, P. J.
    Jassem, J.
    Ma, C. X.
    Fernandes, R.
    Huisden, R.
    Stewart, R.
    Vukovic, P.
    Nunes, A. Tablante
    Nowecki, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S199 - S199
  • [23] TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).
    Meric-Bernstam, Funda
    Spira, Alexander I.
    Lisberg, Aaron Elliott
    Sands, Jacob
    Yamamoto, Noboru
    Johnson, Melissa Lynne
    Yoh, Kiyotaka
    Garon, Edward B.
    Heist, Rebecca Suk
    Petrich, Adam
    Greenberg, Jonathan
    Tajima, Naoyuki
    Kawasaki, Yui
    Gu, Jessie
    Kobayashi, Fumiaki
    Lu, Yasong
    Guevara, Ferdinand M.
    Shimizu, Toshio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
    Ahn, M. J.
    Lisberg, A.
    Paz-Ares, L.
    Cornelissen, R.
    Girard, N.
    Pons-Tostivint, E.
    Baz, D. Vicente
    Sugawara, S.
    Dols, M. Cobo
    Perol, M.
    Mascaux, C.
    Poddubskaya, E.
    Kitazono, S.
    Hayashi, H.
    Sands, J.
    Hall, R.
    Zhang, Y.
    Zebger-Gong, H.
    Uema, D.
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S1305 - S1306
  • [25] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
    Ahn, M-J.
    Lisberg, A. E.
    Paz-Ares, L.
    Cornelissen, R.
    Girard, N.
    Pons-Tostivint, E.
    Vicente Baz, D.
    Sugawara, S.
    Cobo Dols, M.
    Perol, M.
    Mascaux, C.
    Poddubskaya, E.
    Kitazono, S.
    Hayashi, H.
    Sands, J.
    Hall, R.
    Zhang, Y.
    Zebger-Gong, H.
    Uema, D.
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S1665 - S1666
  • [26] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
    Atmaca, Akin
    Ahn, Myung-Ju
    Lisberg, Aaron
    Paz-Ares, Luis
    Cornelissen, Robin
    Girard, Nicolas
    Pons-Tostivint, Elvire
    Baz, David Vicente
    Sugawara, Shunichi
    Cobo, Manuel Angel
    Perol, Maurice
    Mascaux, Celine
    Poddubskaya, Elena
    Kitazono, Satoru
    Hayashi, Hidetoshi
    Sands, Jacob
    Hall, Richard
    Zhang, Yong
    Zebger-Gong, Hong
    Uema, Deise
    Okamoto, Isamu
    Reinmuth, Niels
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 245 - 245
  • [27] AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab plus Carboplatin as 1L Treatment of Advanced/mNSCLC
    Aggarwal, C.
    Cheema, P.
    Arrieta, O.
    Bonanno, L.
    Borghaei, H.
    Hu, Y.
    Kim, D. -W.
    de Castro Junior, G.
    Hepner, A.
    Deng, C.
    del Riego, M. Gonzalez
    Kato, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S305 - S306
  • [28] TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
    Dent, Rebecca A.
    Cescon, David W.
    Bachelot, Thomas
    Jung, Kyung Hae
    Shao, Zhi-Ming
    Saji, Shigehira
    Traina, Tiffany A.
    Vukovic, Petra
    Mapiye, Darlington
    Maxwell, Micah J.
    Schmid, Peter
    Cortes, Javier
    FUTURE ONCOLOGY, 2023, 19 (35) : 2349 - 2359
  • [29] TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy 6 carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC)
    Borghaei, Hossein
    Waqar, Saiama Naheed
    Bruno, Debora S.
    Kitazono, Satoru
    Wakuda, Kazushige
    Spira, Alexander I.
    Olivares, Jairo
    Mak, Gabriel
    Lovick, Susan
    Goodwin, Louise
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01
    Pons-Tostivint, E.
    Okamoto, I.
    Sands, J.
    Girard, N.
    Cornelissen, R.
    Hong, M. H.
    Paz-Ares, L. G.
    Vicente Baz, D.
    Sugawara, S.
    Cobo Dols, M.
    Perol, M.
    Mascaux, C.
    Kitazono, S.
    Hayashi, H.
    Lisberg, A. E.
    Juan Vidal, O. J.
    Zhang, Y.
    Chargualaf, M.
    Uema, D.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2024, 35 : S835 - S836
12345